51 – 60 of 67
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
A new protocol for exercise testing in COPD; improved prediction algorithm for WMAX and validation of the endurance test in a placebo-controlled double bronchodilator study
(
- Contribution to journal › Article
-
Mark
Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening : a post hoc analysis of the EMAX trial
(
- Contribution to journal › Article
- 2020
-
Mark
Type 2 inflammatory biomarker response after exercise challenge testing
(
- Contribution to journal › Article
-
Mark
Salbutamol use in relation to maintenance bronchodilator efficacy in COPD : a prospective subgroup analysis of the EMAX trial
(
- Contribution to journal › Article
-
Mark
Converging pathways in pulmonary fibrosis and Covid-19 - The fibrotic link to disease severity : Common molecular pathways in Covid-19 and pulmonary fibrosis
(
- Contribution to journal › Article
-
Mark
Nordstar : Paving the way for a new era in asthma research
(
- Contribution to journal › Article
-
Mark
A new maximal bicycle test using a prediction algorithm developed from four large COPD studies
(
- Contribution to journal › Article
-
Mark
Clinical characteristics of the BREATHE cohort–a real-life study on patients with asthma and COPD
(
- Contribution to journal › Article
-
Mark
Eosinophils, basophils, and type 2 immune microenvironments in COPD-affected lung tissue
(
- Contribution to journal › Article
-
Mark
Early and sustained symptom improvement with umeclidinium/vilanterol versus monotherapy in COPD : a post hoc analysis of the EMAX randomised controlled trial
(
- Contribution to journal › Article